Loading...

Mainstay Medical International

ISE:MSTY1
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MSTY1
ISE
€31M
Market Cap
  1. Home
  2. IE
  3. Healthcare
Company description

Mainstay Medical International plc, together with its subsidiaries, operates as a medical device company in Europe, the United States, and Australia. The last earnings update was 35 days ago. More info.


Add to Portfolio Compare Print
MSTY1 Share Price and Events
7 Day Returns
0%
ISE:MSTY1
0.7%
Europe Medical Equipment
-0%
IE Market
1 Year Returns
-
ISE:MSTY1
9.6%
Europe Medical Equipment
-13.6%
IE Market
MSTY1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Mainstay Medical International (MSTY1) 0% 0% -6.8% - -76.3% -82.1%
Europe Medical Equipment 0.7% 3.3% 7% 9.6% 58.2% 85.5%
IE Market -0% -5.3% 1.6% -13.6% 0.7% 39.8%
1 Year Return vs Industry and Market
  • No trading data on MSTY1.
  • No trading data on MSTY1.
Price Volatility
MSTY1
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Mainstay Medical International's competitors could be found in our database.

MSTY1 Value

 Is Mainstay Medical International undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Mainstay Medical International. This is due to cash flow or dividend data being unavailable. The share price is €3.82.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Mainstay Medical International's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Mainstay Medical International's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ISE:MSTY1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.65
ENXTPA:MSTY Share Price ** ENXTPA (2019-03-22) in EUR €3.52
ENXTPA:MSTY Share Price converted to USD reporting currency Exchange rate (EUR/ USD) 1.115 $3.93
Europe Medical Equipment Industry PE Ratio Median Figure of 56 Publicly-Listed Medical Equipment Companies 31.99x
Ireland Market PE Ratio Median Figure of 23 Publicly-Listed Companies 11.42x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Mainstay Medical International.

ISE:MSTY1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:MSTY Share Price ÷ EPS (both in USD)

= 3.93 ÷ -3.65

-1.07x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mainstay Medical International is loss making, we can't compare its value to the Europe Medical Equipment industry average.
  • Mainstay Medical International is loss making, we can't compare the value of its earnings to the Ireland market.
Price based on expected Growth
Does Mainstay Medical International's expected growth come at a high price?
Raw Data
ISE:MSTY1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.07x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Medical Equipment Industry PEG Ratio Median Figure of 39 Publicly-Listed Medical Equipment Companies 2.56x
Ireland Market PEG Ratio Median Figure of 19 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Mainstay Medical International, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Mainstay Medical International's assets?
Raw Data
ISE:MSTY1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.37
ENXTPA:MSTY Share Price * ENXTPA (2019-03-22) in EUR €3.52
ENXTPA:MSTY Share Price converted to USD reporting currency Exchange rate (EUR/ USD) 1.115 $3.93
Europe Medical Equipment Industry PB Ratio Median Figure of 138 Publicly-Listed Medical Equipment Companies 3.03x
Ireland Market PB Ratio Median Figure of 33 Publicly-Listed Companies 1.15x
ISE:MSTY1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:MSTY Share Price ÷ Book Value per Share (both in USD)

= 3.93 ÷ 0.37

10.48x

* Primary Listing of Mainstay Medical International.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mainstay Medical International is overvalued based on assets compared to the Europe Medical Equipment industry average.
X
Value checks
We assess Mainstay Medical International's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Mainstay Medical International has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MSTY1 Future Performance

 How is Mainstay Medical International expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
48.5%
Expected annual growth in earnings per share.
Earnings growth vs Low Risk Savings
Is Mainstay Medical International expected to grow at an attractive rate?
  • Mainstay Medical International's earnings growth is expected to exceed the low risk savings rate of 0.9%.
Growth vs Market Checks
  • Mainstay Medical International's earnings growth is expected to exceed the Ireland market average.
  • Mainstay Medical International's revenue growth is expected to exceed the Ireland market average.
Annual Growth Rates Comparison
Raw Data
ISE:MSTY1 Future Growth Rates Data Sources
Data Point Source Value (per year)
ISE:MSTY1 Future Earnings per Share Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 48.5%
ISE:MSTY1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 94.7%
Europe Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 18.8%
Europe Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.2%
Ireland Market Earnings Growth Rate Market Cap Weighted Average 11.9%
Ireland Market Revenue Growth Rate Market Cap Weighted Average 5.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ISE:MSTY1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ISE:MSTY1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 8 1
2019-12-31 3 1
ISE:MSTY1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -27 -31
2018-09-30 1 -28 -32
2018-06-30 0 -28 -33
2018-03-31 0 -27 -31
2017-12-31 0 -25 -30
2017-09-30 0 -23 -27
2017-06-30 0 -21 -23
2017-03-31 0 -19 -21
2016-12-31 -17 -19
2016-09-30 -15 -17
2016-06-30 -13 -16
2016-03-31 -12 -14

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Mainstay Medical International's earnings are expected to grow significantly at over 20% yearly.
  • Mainstay Medical International's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ISE:MSTY1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Mainstay Medical International Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ISE:MSTY1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 -1.46 -1.46 -1.46 1.00
2019-12-31 -1.65 -1.65 -1.65 1.00
ISE:MSTY1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.65
2018-09-30 -4.03
2018-06-30 -4.45
2018-03-31 -4.48
2017-12-31 -4.51
2017-09-30 -4.01
2017-06-30 -3.50
2017-03-31 -3.45
2016-12-31 -3.38
2016-09-30 -3.47
2016-06-30 -3.58
2016-03-31 -3.34

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Mainstay Medical International will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Mainstay Medical International's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Mainstay Medical International has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MSTY1 Past Performance

  How has Mainstay Medical International performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Mainstay Medical International's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Mainstay Medical International does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Mainstay Medical International's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Mainstay Medical International's 1-year growth to the Europe Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Mainstay Medical International's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Mainstay Medical International Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ISE:MSTY1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.66 -31.08 15.10 3.45
2018-09-30 0.56 -32.08 13.75 3.81
2018-06-30 0.46 -33.08 12.41 4.17
2018-03-31 0.40 -31.46 11.63 4.17
2017-12-31 0.35 -29.84 10.86 4.17
2017-09-30 0.30 -26.51 9.16 4.88
2017-06-30 0.25 -23.19 7.46 5.58
2017-03-31 0.13 -20.97 7.55 4.58
2016-12-31 -18.76 7.65 3.58
2016-09-30 -17.24 7.72 2.63
2016-06-30 -15.72 7.79 1.67
2016-03-31 -14.48 6.54 2.28
2015-12-31 -13.24 5.30 2.89
2015-09-30 -13.07 5.39 2.74
2015-06-30 -12.91 5.47 2.58
2015-03-31 -47.69 5.01 2.59
2014-12-31 -82.47 4.54 2.60
2014-09-30 -81.71 4.13 2.69
2014-06-30 -80.96 3.72 2.79
2014-03-31 -45.64 3.59 3.38
2013-12-31 -10.32 3.47 3.98
2012-12-31 -5.88 1.29 2.43

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Mainstay Medical International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Mainstay Medical International has efficiently used its assets last year compared to the Europe Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Mainstay Medical International improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Mainstay Medical International's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Mainstay Medical International has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MSTY1 Health

 How is Mainstay Medical International's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Mainstay Medical International's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Mainstay Medical International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Mainstay Medical International's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Mainstay Medical International's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Mainstay Medical International Company Filings, last reported 4 months ago.

ISE:MSTY1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 3.28 11.95 15.55
2018-09-30 3.28 11.95 15.55
2018-06-30 15.61 13.17 29.71
2018-03-31 15.61 13.17 29.71
2017-12-31 -5.82 14.39 9.98
2017-09-30 -5.82 14.39 9.98
2017-06-30 9.03 15.13 24.50
2017-03-31 9.03 15.13 24.50
2016-12-31 21.06 15.54 36.67
2016-09-30 21.06 15.54 36.67
2016-06-30 30.01 10.73 42.77
2016-03-31 30.01 10.73 42.77
2015-12-31 5.22 10.39 16.62
2015-09-30 5.22 10.39 16.62
2015-06-30 11.38 0.00 12.53
2015-03-31 11.38 0.00 12.53
2014-12-31 16.93 0.00 18.28
2014-09-30 16.93 0.00 18.28
2014-06-30 23.09 0.00 23.48
2014-03-31 23.09 0.00 23.48
2013-12-31 -21.97 25.75 9.59
2012-12-31 -12.08 23.80 17.37
  • Mainstay Medical International's level of debt (363.9%) compared to net worth is high (greater than 40%).
  • Mainstay Medical International had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Mainstay Medical International has less than a year of cash runway based on current free cash flow.
  • Mainstay Medical International has less than a year of cash runway if free cash flow continues to grow at historical rates of 30.1% each year.
X
Financial health checks
We assess Mainstay Medical International's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Mainstay Medical International has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MSTY1 Dividends

 What is Mainstay Medical International's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Mainstay Medical International dividends. Estimated to be 0% next year.
If you bought €2,000 of Mainstay Medical International shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Mainstay Medical International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Mainstay Medical International's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ISE:MSTY1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 40 Stocks 1.5%
Ireland Market Average Dividend Yield Market Cap Weighted Average of 21 Stocks 2.4%
Ireland Minimum Threshold Dividend Yield 10th Percentile 1.2%
Ireland Bottom 25% Dividend Yield 25th Percentile 2.2%
Ireland Top 25% Dividend Yield 75th Percentile 4.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ISE:MSTY1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Mainstay Medical International has not reported any payouts.
  • Unable to verify if Mainstay Medical International's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Mainstay Medical International's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Mainstay Medical International has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Mainstay Medical International's dividends in 3 years as they are not expected to pay a notable one for Ireland.
X
Income/ dividend checks
We assess Mainstay Medical International's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Mainstay Medical International afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Mainstay Medical International has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MSTY1 Management

 What is the CEO of Mainstay Medical International's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jason Hannon
COMPENSATION $722,675
AGE 46
TENURE AS CEO 1.6 years
CEO Bio

Mr. Jason Marshall Hannon, Esq., serves as Director of Kuros Biosciences AG since June 14, 2018. He has been the Chief Executive Officer of Mainstay Medical International plc since October 9, 2017. Mr. Hannon served as Consultant of NuVasive, Inc. since September 1, 2017 until December 31, 2017 and served as its President and Chief Operating Officer from September 11, 2016 to August 1, 2017. Mr. Hannon served as an Executive Vice President of International at NuVasive, Inc. since July 16, 2015 until September 11, 2016 and served as its General Counsel from January 2007 to December 1, 2015. He served as an Executive Vice President of Corporate Development at NuVasive, Inc. from January 1, 2010 to July 2015 and served as its Secretary from January 2007 to July 2015. Mr. Hannon served as Executive Vice President of NuVasive, Inc. since January 1, 2010 and served as its Senior Vice President from January 2007 to January 2009. He served as Senior Vice President of Corporate Development of NuVasive, Inc. from January 2009 to January 1, 2010. He served as Vice President of Legal Affairs at Nuvasive, Inc. from June 14, 2005 to January 2009 and was a Consultant since August 1, 2017 until September 1, 2017. Mr. Hannon was employed at Heller Ehrman LLP. Mr. Hannon served as a Law Clerk to the Honorable Jerome Farris of the U.S. Court of Appeals for the Ninth Circuit. Mr. Hannon practiced corporate and transactional law at the law firms of Brobeck Phleger & Harrison LLP. Mr. Hannon has broad medical device experience has spanned areas like critical commercialization of new products, penetration of new markets, product innovation, strategic and financial planning, raising capital, regulatory and clinical management and the building of a high-performance culture. He has been a Director of Mainstay Medical International plc since October 9, 2017. He served as a Director of Nemaris, Inc. Mr. Hannon holds a B.A. degree from the University of California at Berkeley and a J.D. from Stanford Law School.

CEO Compensation
  • Insufficient data for Jason to compare compensation growth.
  • Jason's remuneration is higher than average for companies of similar size in Ireland.
Management Team Tenure

Average tenure and age of the Mainstay Medical International management team in years:

1.1
Average Tenure
46.5
Average Age
  • The average tenure for the Mainstay Medical International management team is less than 2 years, this suggests a new team.
Management Team

Jason Hannon

TITLE
CEO & Director
COMPENSATION
$723K
AGE
46
TENURE
1.6 yrs

Matt Onaitis

TITLE
CFO & Company Secretary
AGE
47
TENURE
0.8 yrs

Prashant Rawat

TITLE
Chief Operating Officer
AGE
44

Jan Heemels

TITLE
Vice President of Marketing
AGE
55
TENURE
1.3 yrs

Wolfgang Frisch

TITLE
VP & MD of Germany
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the Mainstay Medical International board of directors in years:

3.9
Average Tenure
52.5
Average Age
  • The tenure for the Mainstay Medical International board of directors is about average.
Board of Directors

Oern Stuge

TITLE
Independent Non-Executive Chairman
COMPENSATION
$106K
AGE
64

Jason Hannon

TITLE
CEO & Director
COMPENSATION
$723K
AGE
46
TENURE
1.6 yrs

David Brabazon

TITLE
Independent Non-Executive Director
COMPENSATION
$59K
AGE
48
TENURE
5.1 yrs

James Reinstein

TITLE
Independent Non-Executive Director
COMPENSATION
$59K
AGE
53
TENURE
3.9 yrs

Dan Sachs

TITLE
Non-Executive Director
AGE
53
TENURE
5.1 yrs

Antoine Papiernik-Berkhauer

TITLE
Non-Executive Director
AGE
52
TENURE
5.1 yrs

Nael Kassar

TITLE
Non-Executive Director
AGE
39
TENURE
2.9 yrs

Greg Garfield

TITLE
Non-Executive Director
AGE
55
TENURE
2.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Mainstay Medical International's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Mainstay Medical International has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MSTY1 News

Simply Wall St News

MSTY1 Company Info

Description

Mainstay Medical International plc, together with its subsidiaries, operates as a medical device company in Europe, the United States, and Australia. It develops ReActiv8, an implantable restorative neurostimulation system to treat people with disabling chronic low back pain. The company was formerly known as Mainstay Medical plc and changed its name to Mainstay Medical International plc in March 2014. Mainstay Medical International plc was founded in 2008 and is headquartered in Dublin, Ireland.

Details
Name: Mainstay Medical International plc
MSTY1
Exchange: ISE
Founded: 2008
€30,876,486
8,771,729
Website: http://www.mainstay-medical.com/en
Address: Mainstay Medical International plc
77 Sir John Rogerson’s Quay,
Block C,
Dublin,
Co. Dublin, 2,
Ireland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA MSTY New Ordinary Shares Euronext Paris FR EUR 29. Apr 2014
OTCPK MMDZ.F New Ordinary Shares Pink Sheets LLC US USD 29. Apr 2014
LSE 0QUD New Ordinary Shares London Stock Exchange GB EUR 29. Apr 2014
ISE MSTY1 New Ordinary Shares Irish Stock Exchange IE EUR 29. Apr 2014
BATS-CHIXE MSTYP New Ordinary Shares BATS 'Chi-X Europe' GB EUR 29. Apr 2014
Number of employees
Current staff
Staff numbers
37
Mainstay Medical International employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/23 00:32
End of day share price update: 2019/03/22 00:00
Last estimates confirmation: 2019/04/25
Last earnings filing: 2019/04/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.